Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 8/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7626858 | 1.00 | CTRB1 (0.50) | CTRB1NPC1RAB9ACAPN1CYP1A2 | |
| SCHEMBL28055494 | 0.86 | CTRB1 (0.59) | CTRB1NPC1RAB9ATAAR1ALPI | |
| SCHEMBL7796543 | 0.86 | CTRB1 (0.59) | CTRB1NPC1RAB9ATAAR1ALPI | |
| SCHEMBL27809899 | 0.85 | CAPN1 (0.46) | CTRB1NPC1RAB9ACAPN1CYP1A2 | |
| SCHEMBL7796605 | 0.85 | PSMB8 (0.56) | PSMB8PSMB5 | |
| SCHEMBL7796444 | 0.85 | CTRB1 (0.56) | CTRB1NPC1RAB9ACAPN1ACE | |
| SCHEMBL17865652 | 0.84 | CAPN1 (0.61) | CAPN1ACE | |
| SCHEMBL3292711 | 0.84 | CAPN1 (0.61) | CAPN1ACE | |
| SCHEMBL2369340 | 0.84 | CAPN1 (0.61) | CAPN1ACE | |
| SCHEMBL7796647 | 0.83 | CTSK (0.47) | CTRB1NPC1RAB9ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697348-B1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2011-12-28 | — | — | EP | disclosed |
| US-7696226-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2010-04-13 | — | — | US | disclosed |
| US-20050159469-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159469-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | CTRB1 168/4885NPC1 569/4885RAB9A 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.